hotspot -WSS

hotspot

author：explore 2025-09-28 23:31:16 - browse：129

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Tuberculosis patients need more than just free medication

explore

focus

WSS

Flash flood warnings continue for parts of Missouri, Illinois

FDA clears AI tool for detecting skin cancer

Feed a cold, starve a fever? Here’s what science says

Independent physicians launch a new lobbying group

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Feed a cold, starve a fever? Here’s what science says

explore

hotspot

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

New brain studies show LSD's effects on the brain in full color

Wildfire smoke exposes gaps in outdoor worker protections

Research misconduct: Proposed new rules face resistance

In age of alternative facts, a scholarly course on calling out crap

Dewpoint Therapeutics lays off staff after losing partnerships

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Drug repurposing or repositioning? The language matters

Paxlovid rebound happens. Why and to whom are still a mystery

entertainment

Francis Collins on trust in science and how Covid communications failed

Paxlovid rebound happens. Why and to whom are still a mystery

Many breast cancer patients receive more radiation than needed

Dewpoint Therapeutics lays off staff after losing partnerships

With heat waves through August, officials warn of health risks

Judge in Trump's classified documents case questions use of out

explore

focus

focus

knowledge